Reported results
- Total revenue was $24.3 million for the third quarter of 2026 (GAAP).
- Biologics revenue was $19.3 million for the third quarter of 2026 (GAAP).
- Gross margin for the third quarter of 2026 was 56.3% (GAAP).
- Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share (GAAP).
- Adjusted EBITDA was a loss of $1.5 million for the third quarter of 2026 (non-GAAP).
- Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement grew 8% compared to the second quarter of 2026 (non-GAAP).
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
